WO2018159865A1 - Dispositif d'injection de solution sans aiguille et procédé d'injection de solution sans aiguille l'utilisant - Google Patents
Dispositif d'injection de solution sans aiguille et procédé d'injection de solution sans aiguille l'utilisant Download PDFInfo
- Publication number
- WO2018159865A1 WO2018159865A1 PCT/KR2017/002205 KR2017002205W WO2018159865A1 WO 2018159865 A1 WO2018159865 A1 WO 2018159865A1 KR 2017002205 W KR2017002205 W KR 2017002205W WO 2018159865 A1 WO2018159865 A1 WO 2018159865A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- receiving member
- skin
- insulin
- needleless
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 49
- 239000000243 solution Substances 0.000 claims description 181
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 172
- 238000002347 injection Methods 0.000 claims description 90
- 239000007924 injection Substances 0.000 claims description 90
- 102000004877 Insulin Human genes 0.000 claims description 86
- 108090001061 Insulin Proteins 0.000 claims description 86
- 229940125396 insulin Drugs 0.000 claims description 86
- 238000010438 heat treatment Methods 0.000 claims description 54
- 239000011148 porous material Substances 0.000 claims description 38
- 229910010380 TiNi Inorganic materials 0.000 claims description 24
- 210000003423 ankle Anatomy 0.000 claims description 18
- 210000003491 skin Anatomy 0.000 description 54
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 19
- 238000009792 diffusion process Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 238000001802 infusion Methods 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 210000000707 wrist Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 239000000956 alloy Substances 0.000 description 5
- 229910045601 alloy Inorganic materials 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000009476 short term action Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 230000002746 orthostatic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- WEDIKSVWBUKTRA-WTKGVUNUSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC WEDIKSVWBUKTRA-WTKGVUNUSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010003195 Kallidin Proteins 0.000 description 1
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000455 fourth toe Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000004663 powder metallurgy Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003051 thermoreceptor Anatomy 0.000 description 1
- 108091008689 thermoreceptors Proteins 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
- A61M2005/3022—Worn on the body, e.g. as patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
Definitions
- Insulin infusions which are widely used for diabetic response, offer many advantages, but patients still feel the discomfort and pain associated with several daily administrations by needle injection.
- Insulin injection method that does not use a needle developed so far is to inject insulin into the oral cavity or inhaled through the nose.
- pancreas transplantation is also actively developed as a method for diabetes.
- these methods do not yet provide sufficient effect and are not widely used.
- One proposed method of needleless insulin injection is jet injection, which allows liquid flow to the subcutaneous layer at high speed to allow insulin solution to diffuse through the skin, but this method requires expensive and complex devices, and In principle, not much different.
- Needleless solution injection device for achieving the above technical problem, the body; A solution receiving member exposed to contact the skin of the living body on one side of the body and accommodating a solution; A heating lamp which emits light to heat the solution receiving member and is positioned in the body opposite the solution receiving member; A power source located in the body and supplying power to the heating lamp; And a control unit positioned in the body and electrically connected to and controlling the power supply and the heating lamp, wherein the solution receiving member is heated by the heating lamp so that the solution contacts the solution receiving member. It is injected into the living body through.
- the solution may comprise insulin.
- the solution receiving member has a porosity of 65% to 75% and a pore size distribution of 40 ⁇ m to 900 ⁇ m, and may have an average pore size of 130 ⁇ m to 170 ⁇ m.
- the heating lamp 130 may emit light to heat the solution accommodating member 120, and may be positioned in the body 110 to face the solution accommodating member 120.
- the heat lamp 130 may emit light for heating the solution receiving member 120, and may emit infrared light having a wavelength in a range of about 880 nm to about 1200 nm, for example.
- the heating lamp 130 may include various light sources and may include, for example, a light emitting diode (LED).
- the heating lamp 130 may include, for example, an infrared light emitting diode. Light emitting diodes for such infrared radiation preferably provide small size and high light emission. Infrared emission can be easily controlled by selecting the level of current required for power of the light emitting diodes. Such current control may be performed by the controller 150 described below.
- the power source 140 may be located in the body 110 and may be electrically connected to the heating lamp 130 to supply power.
- the power source 140 may have a structure connected to an external power source or may have a battery structure separated from the outside.
- the power source 140 may include a primary battery that is replaced, for example, a battery, or may include a rechargeable secondary battery.
- the power source 140 may be, for example, a lithium ion battery or a lithium polymer battery.
- FIG. 3 is a photograph showing a solution receiving member 120 included in the needleless solution injection device 100 of FIG. 1, according to an embodiment of the present invention.
- the diffusion process from the porous TiNi base depends on many factors, such as viscosity, specific gravity, density, TiNi permeability, pore size, pore length, surface area in contact with the external environment, and temperature of the porous body.
- the dependence between the rate of change of the fluid volume of the TiNi porous structure and the basic parameters of solution diffusion is expressed by Equation 1 below. :
- the temperature gradient of the contact area between insulin and the skin a temperature gradient occurs in the insulin solution contained in the pores in the solution receiving member as heat (or infrared) is provided by the heating lamp.
- This temperature gradient can be activated by radiating heat provided at the pore walls and intersections.
- heating due to partial absorption of infrared radiation by the surface of the solution receiving member may produce the required temperature gradient. have.
- Patient E age 53 years; Case number # A1263; Diabetes diagnosed 6 years ago during defined determination of blood glucose levels by thirst, polyuria, and family history; And patients have been treated with various combinations of metformin and sulfonylurea over the long term.
- a needleless injector was applied to patient E.
- the clinical cases clearly demonstrate the efficiency of the needleless device for the implementation and efficiency of the administration of insulin through the transdermal. Therefore, it is considered that the medical effect of the needleless solution injection device and method according to the present invention is verified.
- the needleless solution injection device and method according to the technical concept of the present invention can be extended for bioinfusion into other drugs, and thus can be widely applied to medical practice.
- Needle-free solution injection device and method according to the technical concept of the present invention is to accelerate the in vivo injection and absorption of insulin by locally heating the skin corresponding to the insulin injection portion without using a needle, the existing research The results were reviewed.
- 42 insulin patients were clinically verified the efficiency of insulin supply. Specifically, by locally heating the skin by a needleless device, it was effective for infusion and absorption of insulin without increasing the risk of hypoglycemia. This local skin heating can cause the loop to close and increase the overall insulin supply. It is also analyzed that increasing the temperature of the skin at the infusion site does not cause other side effects in the patient and is therefore sufficient to increase the infusion of insulin.
- the needleless injection device and method according to the technical concept of the present invention do not cause skin irritation or lesions and are safe to use.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
La présente invention concerne un dispositif d'injection de solution sans aiguille qui peut injecter une solution dans un corps vivant sans l'utilisation d'une aiguille. Le dispositif d'injection de solution sans aiguille de la présente invention comprend : un corps; un élément de maintien de solution qui maintient une solution et est disposé sur un côté du corps tout en étant exposé de façon à entrer en contact avec la peau d'un corps vivant; une lampe à chaleur qui émet de la lumière pour chauffer l'élément de maintien de solution et est disposée à l'opposé de l'élément de maintien de solution dans le corps; une alimentation électrique disposée dans le corps pour fournir de l'énergie à la lampe à chaleur; et une unité de commande disposée dans le corps et connectée électriquement à l'alimentation électrique et à la lampe à chaleur pour commander celle-ci, l'élément de maintien de solution étant chauffé par la lampe à chaleur, et ainsi la solution étant injectée dans le corps vivant à travers la peau en contact avec l'élément de maintien de solution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170025945A KR101887088B1 (ko) | 2017-02-28 | 2017-02-28 | 무 바늘 용액 주입 장치 및 이를 이용한 무 바늘 용액 주입 방법 |
| KR10-2017-0025945 | 2017-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018159865A1 true WO2018159865A1 (fr) | 2018-09-07 |
Family
ID=63251313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2017/002205 WO2018159865A1 (fr) | 2017-02-28 | 2017-02-28 | Dispositif d'injection de solution sans aiguille et procédé d'injection de solution sans aiguille l'utilisant |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101887088B1 (fr) |
| WO (1) | WO2018159865A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102168759B1 (ko) * | 2018-11-01 | 2020-10-22 | 주식회사 에스티엔 | 약액 주입기 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5533995A (en) * | 1991-11-13 | 1996-07-09 | Elan Corporation, Plc | Passive transdermal device with controlled drug delivery |
| JP2000513336A (ja) * | 1996-05-22 | 2000-10-10 | ディバーシファイド ファーマシューティカルズ，インコーポレーテッド | 薬物の経皮送達のための組成物、方法及びデバイス |
| JP2002525172A (ja) * | 1998-09-29 | 2002-08-13 | ザース・インコーポレーテッド | 薬剤活性化合物の改良された適用方法及び装置 |
| KR20040012903A (ko) * | 2003-12-05 | 2004-02-11 | 주식회사 바이오스마트 | 소화기관자극기 |
| KR20090128499A (ko) * | 2007-03-19 | 2009-12-15 | 인슐린 메디컬 엘티디 | 약물 전달 장치 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4622031A (en) * | 1983-08-18 | 1986-11-11 | Drug Delivery Systems Inc. | Indicator for electrophoretic transcutaneous drug delivery device |
| KR100692501B1 (ko) * | 1999-03-16 | 2007-03-09 | 문형대 | 발열체를 이용한 활성물질의 피부 흡수패드 |
| US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
| DE102006023186B4 (de) * | 2006-05-17 | 2012-02-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Transdermales therapeutisches System |
| EP2268244B1 (fr) * | 2008-03-31 | 2018-07-04 | Nitto Denko Corporation | Système d'administration de perméant et procédés d'utilisation de celui-ci |
| CN102245137A (zh) * | 2008-11-07 | 2011-11-16 | 茵苏莱恩医药有限公司 | 用于药物递送的装置和方法 |
-
2017
- 2017-02-28 WO PCT/KR2017/002205 patent/WO2018159865A1/fr active Application Filing
- 2017-02-28 KR KR1020170025945A patent/KR101887088B1/ko active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5533995A (en) * | 1991-11-13 | 1996-07-09 | Elan Corporation, Plc | Passive transdermal device with controlled drug delivery |
| JP2000513336A (ja) * | 1996-05-22 | 2000-10-10 | ディバーシファイド ファーマシューティカルズ，インコーポレーテッド | 薬物の経皮送達のための組成物、方法及びデバイス |
| JP2002525172A (ja) * | 1998-09-29 | 2002-08-13 | ザース・インコーポレーテッド | 薬剤活性化合物の改良された適用方法及び装置 |
| KR20040012903A (ko) * | 2003-12-05 | 2004-02-11 | 주식회사 바이오스마트 | 소화기관자극기 |
| KR20090128499A (ko) * | 2007-03-19 | 2009-12-15 | 인슐린 메디컬 엘티디 | 약물 전달 장치 |
Non-Patent Citations (1)
| Title |
|---|
| GUNTHER, S. V.: "Porous TiNi-based material and infrared radiation in needle-free treatment of diabetic patients", ADVANCED MATERIALS LETTERS, vol. 7, no. 9, 2016, pages 713 - 718, XP055539138 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101887088B1 (ko) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Wearable glucose monitoring and implantable drug delivery systems for diabetes management | |
| Zheng et al. | Iontophoresis-driven microneedle patch for the active transdermal delivery of vaccine macromolecules | |
| Wu et al. | Materials, devices and systems of soft bioelectronics for precision therapy | |
| ES2683830T3 (es) | Bomba de infusión portátil que tiene comunicación por acoplamiento capacitivo y mecanismo de recuperación de energía | |
| KR101509827B1 (ko) | 약물 전달 방법 및 장치 | |
| ES2766956T3 (es) | Bomba parche flexible y adaptable | |
| US8622991B2 (en) | Method and device for drug delivery | |
| US9220837B2 (en) | Method and device for drug delivery | |
| US20080208162A1 (en) | Device and Method For Thermophoretic Fluid Delivery | |
| US20180369064A1 (en) | Devices and methods for increased blood flow, healing, and pain control | |
| EP1117357B1 (fr) | Dispositifs servant à ameliorer l'administration de composes actifs sur le plan pharmaceutique | |
| US20080086063A1 (en) | Apparatus and method for the reduction of pain using vibration, cold and distractive elements | |
| CN108310615A (zh) | 一种光诱导微针透皮给药装置 | |
| JP2002525297A (ja) | フェンタニールおよびスフェンタニールの改良された投与の方法および装置 | |
| JP2017503604A (ja) | Ａｂｒｅｕ脳熱トンネルでの治療を提供するように構成されたデバイス | |
| Cao et al. | Sustained release of insulin from silk microneedles | |
| WO2018159865A1 (fr) | Dispositif d'injection de solution sans aiguille et procédé d'injection de solution sans aiguille l'utilisant | |
| CN113546294A (zh) | 一种微针自助检测治疗装置 | |
| WO2010088914A1 (fr) | Dispositif de régulation du débit sanguin sous-cutané | |
| KR20210098605A (ko) | 약물 주입 시스템용 조직 뭉침 방지 시스템 | |
| CN108543155A (zh) | 一种可重复换药胰岛素泵 | |
| Han et al. | Synergistic strategies of biomolecular transport technologies in transdermal healthcare systems | |
| CN207544386U (zh) | 一种糖尿病患者病员服 | |
| CN212491134U (zh) | 一种微针自助检测治疗装置 | |
| RU2534521C2 (ru) | Способ трансдермального введения инсулина и устройство для его осуществления |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17898576 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17898576 Country of ref document: EP Kind code of ref document: A1 |